EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ARV-825 Showed Antitumor Activity against BRD4-NUT Fusion Protein by Targeting the BRD4

Liu Yang, Yue Jing, Xia Xia iD, Xiushan Yin iD

Journal of Oncology · 14.12.2023 · 2023 · 1-12

DOI: 10.1155/2023/9904143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Oncology, erschienen am 14.12.2023. Verfasst von Liu Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Applied Biology Laboratory, College of Pharmaceutical and Biological Engineering, Shenyang University of Chemical Technology, Shenyang 110142, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, 2023 Ganzhou City Technology Innovation Center.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The bromodomain-containing 4 (BRD4) is a member of the bromodomain and extra terminal domain (BET) family, which is an important epigenetic reader. It is currently a promising oncology target. In some tumors, BET bromodomain inhibitors have demonstrated promising results. Proteolysis-targeting methods (PROTAC), which rapidly and effectively degrade BRD4, have displayed considerable potential in the treatment of tumors in recent years. The purpose of this study is to examine the potential impact of BRD4 PROTAC compounds ARV-825 on oncogene BRD4-NUT fused protein in NUT carcinoma.

Methods

The effectiveness of ARV-825 was evaluated at the cellular level using the cell counting kit 8 test, wound healing, cell transfection, western blotting analysis, and RNA sequencing. The effectiveness of ARV-825 was also examined in vivo using a xenograft model.

Results

The BRD4-NUT fusion gene was overexpressed in 3T3 cells, and the pathogenic fusion gene was simulated. The results showed that the overexpression of BRD4-NUT could promote the proliferation and migration of 3T3 cells, but the expression of BRD4 protein was degraded after the addition of the novel cereblon-based PROTAC compound ARV-825 against BRD4, resulting in inhibition of BRD4-NUT 3T3 cell proliferation and migration. Further RNA-seq analysis showed that overexpression of BRD4-NUT was accompanied by increased expression of gene (e.g., Myc, E2F, TRAFs, Wnt, Gadd45g, and Sox6) with significantly enriched pathway (e.g., small cell lung cancer, NF-kappa B signaling pathway, and breast cancer), promoted cell cycle from G 1 phase to S phase, and increased cell proliferation and migration, activated the antiapoptosisi signal, led to abnormal cell growth, and ultimately led to tumorigenesis. The addition of ARV-825 effectively rescued this process and effectively inhibited cell vitality, proliferation, and migration. In vivo studies demonstrated that treatment with ARV-825 greatly suppressed tumor growth without causing harmful side effects and downregulated the BRD4-NUT expression level.

Conclusion

Through the induction of BRD4 protein degradation, ARV-825 can successfully limit BRD4-NUT 3T3 cell proliferation in vitro and in vivo. These findings suggested that the BRD4 inhibitor ARV-825 would be an effective therapeutic strategy for treating NUT carcinoma that with the genetic feature of BRD4-NUT fusion event.

Autor:innen und Institutionen

  • Applied Biology Laboratory, College of Pharmaceutical and Biological Engineering, Shenyang University of Chemical Technology, Shenyang 110142, China.
  • State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China.
  • Roc Rock Biotechnology (Shenzhen), Shenzhen 518118, China.

ORCID-Profile: Xia Xia, Xiushan Yin

Förderung

  • National Natural Science Foundation of China
  • 2023 Ganzhou City Technology Innovation Center

Zitieren

APA

Yang, L., Jing, Y., Xia, X., & Yin, X. (2023). ARV-825 Showed Antitumor Activity against BRD4-NUT Fusion Protein by Targeting the BRD4. Journal of Oncology, 2023, 1-12. https://doi.org/10.1155/2023/9904143

Vancouver

Yang L, Jing Y, Xia X, Yin X. ARV-825 Showed Antitumor Activity against BRD4-NUT Fusion Protein by Targeting the BRD4. Journal of Oncology. 2023;2023:1-12. doi:10.1155/2023/9904143

BibTeX
@article{Yang2023,
  author = {Yang, Liu and Jing, Yue and Xia, Xia and Yin, Xiushan},
  title = {ARV-825 Showed Antitumor Activity against BRD4-NUT Fusion Protein by Targeting the BRD4},
  journal = {Journal of Oncology},
  year = {2023},
  volume = {2023},
  pages = {1--12},
  doi = {10.1155/2023/9904143}
}
Kostenlos starten →